AZD3152
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 30, 2022 (NCT05648110)
Timeline
Indications
Studied for
Mechanism of action
- Spike glycoproteinANTAGONIST
Spike glycoprotein antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06057064 | Phase 2 | Sep 29, 2023 | AstraZeneca |
| NCT05932641 | Phase 1 | Jul 31, 2023 | AstraZeneca |
| NCT05872958 | Phase 1 | May 19, 2023 | AstraZeneca |
| NCT05648110 | Phase 3 | Dec 30, 2022 | AstraZeneca |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 3 | 2022 |
1 organizations
Page 1 / 1